1. Academic Validation
  2. GSTP1 improves CAR-T cell proliferation and cytotoxicity to combat lymphoma

GSTP1 improves CAR-T cell proliferation and cytotoxicity to combat lymphoma

  • Front Immunol. 2025 Sep 26:16:1665407. doi: 10.3389/fimmu.2025.1665407.
Guangsong Xu # 1 Jiani Wang # 1 Yuliang Qu # 1 Jing Ning 2 Yanting Zhang 3 Guangxian Xu 4 Yunxia Shi 1 Ying Li 1 Le Guo 5 Xuebo Han 1 Hongxia Wang 1
Affiliations

Affiliations

  • 1 College of Laboratory Medicine, Ningxia Medical University, Yinchuan, Ningxia, China.
  • 2 Hematology Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
  • 3 Gastroenterology Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
  • 4 Medical Technology College, Guangdong Medical University, Dongguan, Guangdong, China.
  • 5 Key Laboratory of Clinical Pathogenic Microbiology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
  • # Contributed equally.
Abstract

Introduction: The exhaustion of chimeric antigen receptor T cells (CAR-T) hampers the efficacy of CAR-T cell therapy. Persistent antigen stimulation in T cells results in a surge of intracellular Reactive Oxygen Species (ROS). ROS, as mitochondrial metabolites, alter the integrity of the mitochondrial membrane and promote T-cell exhaustion. Glutathione S-transferase Pi-1 (GSTP1), a member of the glutathione S-transferase family, is an important enzyme in the intracellular clearance of ROS. Overexpression of GSTP1 may enhance the antitumor capability of CAR-T cells.

Methods: The correlations between GSTP1 and genes related to T-cell exhaustion were analyzed using the TIMER database. Peripheral blood mononuclear cells (PBMCs) were collected from patients with hematologic malignancies (n = 61) and healthy donors (n = 45) to measure GSTP1, B-lymphocyte maturation protein 1 (BLIMP1), and programmed cell death protein 1 (PD-1) expression by qRT-PCR. A T-cell exhaustion model was established to assess GSTP1 expression by Western blotting. The dual-luciferase assay and ChIP-qPCR were used to determine whether the transcription factor BLIMP1 negatively regulated the activity of the GSTP1 promoter. CD19 CAR-T, GSTP1 overexpressing CAR-T (GSTP1 CAR-T), and GSTP1-knockdown CAR-T (shGSTP1 CAR-T) cells were generated to evaluate their antitumor capacity.

Results: GSTP1 expression was downregulated when BLIMP1 and PD-1 were upregulated in PBMCs of Cancer patients and in the in vitro T-cell exhaustion model. Meanwhile, ROS levels in the T-cell exhaustion model increased. Mechanistically, the BLIMP1 transcription factor negatively regulated the activity of the GSTP1 promoter. Based on these findings, we engineered GSTP1 CAR-T cells, which exhibited improved functionality. GSTP1 CAR-T cells increased the TEMRA population, enhanced proliferation and cytotoxicity, elevated antioxidant capacity, increased IL-2 and IFN-γ secretion, reduced the expression of immune checkpoints, and decreased Apoptosis. In vivo, the residual levels of GSTP1 CAR-T cells were higher than those of Cluster of Differentiation 19 (CD19) CAR-T cells and shGSTP1 CAR-T cells, indicating that GSTP1 CAR-T cells exhibited a strong antitumor capacity.

Conclusion: BLIMP1 directly suppressed GSTP1 transcription, whereas GSTP1 overexpression enhanced the antitumor capacity of CAR-T cells and maintained redox homeostasis, providing a novel therapeutic strategy to improve CAR-T cell immunotherapy.

Keywords

BLIMP1; CAR-T cell exhaustion; GSTP1; oxidative stress; reactive oxygen species.

Figures
Products